Barings LLC grew its stake in Eli Lilly And Co (NYSE:LLY) by 16.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 99,859 shares of the company’s stock after buying an additional 13,940 shares during the period. Barings LLC’s holdings in Eli Lilly And Co were worth $8,521,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. BlackRock Inc. increased its position in Eli Lilly And Co by 3.0% in the first quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock worth $5,089,436,000 after buying an additional 1,926,334 shares in the last quarter. Franklin Resources Inc. increased its position in Eli Lilly And Co by 14.1% in the first quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock worth $2,517,762,000 after buying an additional 4,022,251 shares in the last quarter. Schroder Investment Management Group increased its position in Eli Lilly And Co by 103.8% in the first quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock worth $362,806,000 after buying an additional 2,388,548 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Eli Lilly And Co by 2.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 4,335,040 shares of the company’s stock worth $335,403,000 after buying an additional 85,455 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Eli Lilly And Co by 5.1% in the second quarter. Fisher Asset Management LLC now owns 3,710,066 shares of the company’s stock worth $316,580,000 after buying an additional 180,855 shares in the last quarter. Institutional investors and hedge funds own 76.62% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $99.58, for a total transaction of $18,920,200.00. Following the completion of the sale, the insider now owns 120,946,601 shares in the company, valued at $12,043,862,527.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christi Shaw sold 8,426 shares of the stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $82.10, for a total value of $691,774.60. The disclosure for this sale can be found here. Insiders have sold 1,520,728 shares of company stock valued at $136,180,714 in the last quarter. 0.11% of the stock is currently owned by company insiders.

LLY has been the subject of a number of analyst reports. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Monday, April 9th. Jefferies Financial Group set a $90.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Friday, April 13th. BMO Capital Markets upgraded Eli Lilly And Co from an “underperform” rating to a “market perform” rating and upped their price target for the stock from $74.00 to $79.00 in a research report on Friday, April 13th. They noted that the move was a valuation call. HC Wainwright restated a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, April 18th. Finally, Credit Suisse Group set a $80.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Sunday, April 22nd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. Eli Lilly And Co has a consensus rating of “Hold” and an average target price of $100.13.

NYSE:LLY opened at $102.00 on Tuesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $102.59. The stock has a market cap of $108.02 billion, a P/E ratio of 23.83, a price-to-earnings-growth ratio of 1.67 and a beta of 0.27.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. During the same quarter last year, the business posted $1.11 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. research analysts anticipate that Eli Lilly And Co will post 5.47 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be given a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.21%. The ex-dividend date is Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.